AUPH News and Press, Aurinia Pharmaceuticals Inc From 04/11/23

New method of use patent (U.S. Patent No. 11,622,991) issued for LUPKYNIS Reflects the unique and proprietary dosing regimen indicated for LUPKINIS in Lupus Nephritis Announcement is a follow-up to previously announced allowance from the USPTO on application (No. 17,713/140); now ...

2023-04-05 07:07:11 ET Aurinia Pharmaceuticals ( NASDAQ: AUPH ) said biopsy data collected from its phase 3 program AURORA showed promising long term results for its oral drug Lupkynis to treat adults with active lupus nephritis (LN). LN is a type of kidney disease cau...

LUPKYNIS ® treated patients showed histologic activity improvement with stable chronicity scores similar to active control arm of mycophenolate mofetil (MMF) and low dose steroids alone Data further reinforces differentiation of LUPKYNIS from first generation calcineurin inhibito...

2023-03-24 04:47:31 ET Summary Aurinia Pharmaceuticals' Lupkynis revenue figures aren't bad this quarter. However, the target population is the problem. I still think only a buyout from big pharma will unlock full potential. I covered Aurinia Pharmaceuticals ( ...

2023-03-24 00:53:15 ET Summary LUPKYNIS has had a lengthy and ultimately productive development pathway. Aurinia has gone all hands on deck to provide LUPKYNIS a successful launch. Forward earnings prospects are challenged by Aurinia's meager pipeline and by significant compet...

2023-03-23 15:56:20 ET Aurinia Pharmaceuticals ( NASDAQ: AUPH ) rose 6.5% amid renewed takeover speculation. There's speculation than unnamed suitor may be eyeing a takeover of Aurinia ( AUPH ), according to a Betaville "uncooked" alert, which cited people followin...

2023-03-23 06:22:38 ET Summary Aurinia Pharmaceuticals Inc. has strengthened its patent position in the industry and now has more clout as a marketer than just a developer of therapies. Its lead product, LUPKYNIS, an immunosuppressive drug for lupus nephritis, appears to be a high...

2023-03-21 17:57:26 ET Summary Despite positive results from the AURA-LV study, Lupkynis has not become the preferred LN treatment, leading to Aurinia's missed 2022 revenue projections. A study indirectly comparing drug regimens for LN induction therapy indicates tacrolimus plus M...

Aurinia Pharmaceuticals Inc. (AUPH) Q4 2022 Earnings Conference Call February 28, 2023 8:30 AM ET Company Participants Dana Lynch - Director of Corporate Communications & Corporate Affairs Peter Greenleaf - President & Chief Executive Officer Joe Miller - Chief...

Aurinia Pharmaceuticals ( NASDAQ: AUPH ) stock rose ~8% on Tuesday after Q4 net loss narrowed and revenue grew Y/Y. Net loss was -$26.05M, compared to -$33.32M in Q4 2021. Total net revenue grew +21.5% Y/Y to ~$28.44M, however it missed analysts estimates. Full year 2...